NCT04260802 2026-01-12
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
Phase 1/2 Terminated
Clinical Trials
9 trialsNCT04725331 2025-11-21
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Transgene
Phase 1/2 Terminated
NCT03901573 2025-10-22
High-Risk Skin Cancers With Atezolizumab Plus NT-I7
NeoImmuneTech
Phase 1/2 Terminated
NCT03747484 2025-03-06
Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT04590781 2023-04-20
DUET-1-02
Xencor, Inc.
Phase 1/2 Terminated
NCT03435640 2023-03-08
REVEAL
Nektar Therapeutics
Phase 1/2 Terminated
NCT03684785 2022-04-07
Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors
Exicure, Inc.
Phase 1/2 Terminated
NCT02584829 2022-03-22
Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma
Fred Hutchinson Cancer Center
Phase 1/2 Terminated
NCT01758458 2017-04-19
Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma
Fred Hutchinson Cancer Center
Phase 1/2 Terminated